查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1422809

2024-2032 年按技术、治疗领域、最终用户和地区分類的人类绒毛膜促性腺激素市场报告

Human Chorionic Gonadotropin Market Report by Technology, Therapeutic Area, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球人绒毛膜促性腺激素（HCG）市场规模达到9.735亿美元。展望未来， IMARC Group预计到2032年市场规模将达到17.684亿美元，2024-2032年復合年增长率（CAGR）为6.65 %。女性不孕症发病率的上升、性腺机能减退相关疾病盛行率的增加以及使用重组技术生产 HCG 是推动市场发展的一些关键因素。

人类绒毛膜促性腺激素（HCG）是怀孕期间胎盘合体滋养层细胞产生的化学物质。它存在于血液、尿液、肝臟、结肠和脑下垂体。 HCG 刺激黄体产生黄体酮以维持怀孕。它是透过离子交换层析、染料亲和色谱、奈米滤和反相高效液相层析 (HPLC) 等多种技术从孕妇的尿液中提取和纯化用于临床应用。 HCG 广泛用于治疗不孕症、增加怀孕机会、帮助睪固酮和精子的产生以及治疗男孩隐睪症。它还有助于诊断和监测与妊娠相关的疾病、产前筛检和妇科癌症。

人类绒毛膜促性腺激素 (HCG) 市场趋势：

由于子宫疾病、输卵管阻塞、多囊性卵巢症候群（PCOS）和内分泌系统疾病导致的女性不孕症发生率上升是推动市场成长的关键因素之一。 HCG广泛应用于各种辅助生殖技术，如体外受精（IVF）和子宫内人工授精（IUI），以治疗女性不孕症，因为它有助于诱导排卵，促进胚胎形成，促进卵母细胞的正确时机检索，增加子宫内膜厚度，提高子宫内膜容受性。除此之外，与其他生育药物结合使用以增加女性怀孕机会的广泛产品也是另一个生长诱导因素。此外，由于患有肥胖和第2型糖尿病的男性性腺机能减退相关疾病的盛行率不断增加，HCG越来越多地应用于提高睪固酮水平、增强生育能力和促进性功能，这有利于市场的成长。此外，与天然来源的 HCG 相比，使用重组技术生产的 HCG 具有相同的特性、增强的功效和更高的安全性，并增强患者的耐受性，这对市场成长产生了积极影响。其他因素，包括医疗保健基础设施的快速发展、不孕症治疗和服务的不断增加、老年人口的增加、为推出新型纯化和提取技术而进行的广泛研究和开发（R＆D）活动，以及实施各种政府措施改善人们的性健康，预计将进一步推动市场成长。

本报告回答的关键问题：

  • 迄今为止，全球人类绒毛膜促性腺激素（HCG）市场表现如何，未来几年将如何表现？
  • 全球人类绒毛膜促性腺激素 (HCG) 市场的驱动因素、限制因素和机会是什么？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的人类绒毛膜促性腺激素 (HCG) 市场？
  • 基于技术的市场区隔是什么？
  • 基于治疗领域的市场区隔是什么？
  • 基于最终用户的市场区隔是什么？
  • 全球人类绒毛膜促性腺激素（HCG）市场的竞争结构如何？
  • 全球人类绒毛膜促性腺激素 (HCG) 市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球人类绒毛膜促性腺激素 (HCG) 市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依技术

  • 天然来源萃取
    • 市场走向
    • 市场预测
  • 重组技术
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依治疗领域

  • 女性不孕症治疗
    • 市场走向
    • 市场预测
  • 男性性腺功能减退症
    • 市场走向
    • 市场预测
  • 少精治疗
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 生育诊所
    • 市场走向
    • 市场预测
  • 研究机构
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Biocare Medical LLC
    • Ferring Pharmaceuticals
    • Fresenius SE & Co. KGaA
    • Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
    • Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
    • Merck & Co. Inc.
    • Prospec-Tany Technogene Ltd.
    • Scripps Laboratories Inc.
    • Sun Pharmaceutical Industries Limited
Product Code: SR112024A7059

Abstract

The global human chorionic gonadotropin (HCG) market size reached US$ 973.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,768.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.65% during 2024-2032. The rising incidences of infertility in women, increasing prevalence of hypogonadism-related disorders, and production of HCG using recombinant technology represent some of the key factors driving the market.

Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.

Human Chorionic Gonadotropin (HCG) Market Trends:

The rising incidences of infertility among females due to uterine disorders, blocked fallopian tube, polycystic ovarian syndrome (PCOS), and endocrine system disorders are among the key factors driving the market growth. HCG is widely used in various assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility, as it aids in inducing ovulation, promotes the formation of the embryo, facilitates correct timing of oocyte retrieval, increases endometrial thickness, and improve endometrial receptivity. In addition to this, the widespread product utilization in combination with other fertility drugs to increase the chances of pregnancy in women is acting as another growth-inducing factor. Furthermore, the increasing application of HCG to improve testosterone levels, enhance fertility, and promote sexual function due to the increasing prevalence of hypogonadism-related disorders in males suffering from obesity and type 2 diabetes is favoring the market growth. Additionally, the production of HCG using recombinant technology that provides identical properties, enhanced efficacy, and improved safety compared to naturally sourced HCG and enhances patient tolerance is positively influencing the market growth. Other factors, including the rapid development of healthcare infrastructure, increasing availability of treatment and services regarding infertility, rising geriatric population, extensive research and development (R&D) activities for the launch of novel purification and extraction technologies, and the implementation of various government initiatives to improve the sexual health of people, are anticipated to drive the market growth further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global human chorionic gonadotropin (HCG) market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, therapeutic area, and end user.

Technology Insights:

Natural Source Extraction

Recombinant Technology

The report has also provided a detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the technology. This includes natural source extraction and recombinant technology. According to the report, natural source extraction represented the largest segment.

Therapeutic Area Insights:

Female Infertility Treatment

Male Hypogonadism

Oligospermic Treatment

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the therapeutic area has been provided in the report. This includes female infertility treatment, male hypogonadism, oligospermic treatment, and others. According to the report, female infertility treatment accounted for the largest market share.

End User Insights:

Fertility Clinics

Research Institutions

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the end user has been provided in the report. This includes fertility clinics, research institutions, and others. According to the report, fertility clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for human chorionic gonadotropin (HCG). Some of the factors driving the North America human chorionic gonadotropin (HCG) market include rising incidences of infertility among women, growing consumer awareness regarding the available treatment for infertility and gynecological concerns, and rising expenditure capacities of consumers.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global human chorionic gonadotropin (HCG) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc.

Key Questions Answered in This Report:

  • How has the global human chorionic gonadotropin (HCG) market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global human chorionic gonadotropin (HCG) market?
  • What are the key regional markets?
  • Which countries represent the most attractive human chorionic gonadotropin (HCG) markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global human chorionic gonadotropin (HCG) market?
  • Who are the key players/companies in the global human chorionic gonadotropin (HCG) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Chorionic Gonadotropin (HCG) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Natural Source Extraction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Recombinant Technology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Area

  • 7.1 Female Infertility Treatment
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Male Hypogonadism
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oligospermic Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Fertility Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutions
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocare Medical LLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Ferring Pharmaceuticals
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Fresenius SE & Co. KGaA
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Prospec-Tany Technogene Ltd.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Scripps Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sun Pharmaceutical Industries Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Human Chorionic Gonadotropin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Human Chorionic Gonadotropin Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Human Chorionic Gonadotropin Market: Breakup by Therapeutic Area (in %), 2023
  • Figure 6: Global: Human Chorionic Gonadotropin Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Human Chorionic Gonadotropin Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Human Chorionic Gonadotropin (Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Human Chorionic Gonadotropin (Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Human Chorionic Gonadotropin (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Human Chorionic Gonadotropin (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Human Chorionic Gonadotropin Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Human Chorionic Gonadotropin Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Human Chorionic Gonadotropin Industry: Value Chain Analysis
  • Figure 77: Global: Human Chorionic Gonadotropin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Chorionic Gonadotropin Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
  • Table 4: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Human Chorionic Gonadotropin Market: Competitive Structure
  • Table 7: Global: Human Chorionic Gonadotropin Market: Key Players